Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$8.84 - $22.64 $23,196 - $59,407
-2,624 Reduced 36.51%
4,563 $63,000
Q2 2023

Aug 07, 2023

BUY
$8.75 - $14.29 $22,960 - $37,496
2,624 Added 57.51%
7,187 $74,000
Q1 2023

May 11, 2023

BUY
$7.99 - $11.02 $36,458 - $50,284
4,563 New
4,563 $42,000
Q2 2018

Jul 24, 2018

SELL
$48.35 - $65.33 $256,980 - $347,228
-5,315 Closed
0 $0
Q1 2018

Apr 12, 2018

SELL
$38.64 - $57.54 $711,942 - $1.06 Million
-18,425 Reduced 77.61%
5,315 $264,000
Q4 2017

Jan 18, 2018

SELL
$27.28 - $43.26 $23,269 - $36,900
-853 Reduced 3.47%
23,740 $884,000
Q3 2017

Oct 13, 2017

BUY
$17.15 - $32.72 $421,769 - $804,682
24,593
24,593 $775,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $361M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.